Abstract
5542 Background: Trebananib, an investigational recombinant peptide Fc-fusion protein, targets Ang1 and 2. In TRINOVA-1, a randomized phase 3 study, trebananib plus paclitaxel (P) compared with placebo plus P significantly improved PFS (primary endpoint) in recurrent ovarian cancer. Biomarker evaluation was an exploratory endpoint. Methods: Women (≥ 18 years, GOG ≤ 1) with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer received trebananib 15 mg/kg IV QW or placebo IV QW plus P 80 mg/m2 IV QW (3 wks on/1 wk off). Serum samples were collected pre-infusion at wk 1 to evaluate baseline levels of Ang1, Ang2, and soluble Tie2 (sTie2). Analytes were quantified using enzyme-linked immunosorbent assays (ELISA; RD 2) evaluation of Ang1, Ang2, sTie2,...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
